Quick Answer
BIOCRYST PHARMACEUTICALS INC reported Cash and Equivalents of $89.74 million for fiscal year 2025.
BIOCRYST PHARMACEUTICALS INC Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $89.74M | -14.3% |
| 2024 | $104.71M | -5.4% |
| 2023 | $110.64M | -63.7% |
| 2022 | $304.77M | -39.6% |
| 2021 | $504.39M | +85.4% |
| 2020 | $272.13M | +138.3% |
| 2019 | $114.17M | +327.1% |
| 2018 | $26.73M | -46.8% |
| 2017 | $50.28M | +127.5% |
| 2016 | $22.10M | -23.5% |
| 2015 | $28.90M | -47.0% |
| 2014 | $54.54M | +157.7% |
| 2013 | $21.16M | +1.3% |
| 2012 | $20.89M | +27.0% |
| 2011 | $16.44M | +20.7% |
| 2010 | $13.62M | -66.9% |
| 2009 | $41.12M | +84.1% |
| 2008 | $22.34M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $84.08M | -13.2% | -4.5% |
| June 30, 2025 | $88.03M | +12.3% | -16.3% |
| March 31, 2025 | $105.19M | +24.7% | +0.5% |
| December 31, 2024 | $104.71M | -5.4% | +8.1% |
| September 30, 2024 | $96.84M | -35.8% | +23.5% |
| June 30, 2024 | $78.41M | -46.4% | -7.0% |
| March 31, 2024 | $84.33M | -45.6% | -23.8% |
| December 31, 2023 | $110.64M | -63.7% | -26.7% |
- BIOCRYST PHARMACEUTICALS INC showed a decrease of -14.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, BIOCRYST PHARMACEUTICALS INC’s cash and equivalents has grown by 301.6% (from $22.34 million to $89.74 million).
- The most recent figure is from BIOCRYST PHARMACEUTICALS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: